GenSight Biologics 将来の成長

Future 基準チェック /26

GenSight Biologicsの収益は年間49%で減少すると予測されていますが、年間収益は年間33.5%で増加すると予想されています。EPS は年間57%で減少すると予想されています。

主要情報

-49.0%

収益成長率

-57.0%

EPS成長率

Biotechs 収益成長	4.6%
収益成長率	33.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Oct 2024

今後の成長に関する最新情報

Recent updates

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

Dec 22

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 14

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

May 10

Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long

Feb 02

A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary

Dec 09

業績と収益の成長予測

ENXTPA:SIGHT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	6	-66	-64	-64	1
12/31/2025	7	-36	-34	-34	2
12/31/2024	5	-25	-22	-22	2
6/30/2024	2	-20	-16	-16	N/A
3/31/2024	2	-23	-20	-20	N/A
12/31/2023	3	-26	-25	-25	N/A
9/30/2023	3	-28	-29	-29	N/A
6/30/2023	3	-29	-33	-33	N/A
3/31/2023	4	-28	-34	-34	N/A
12/31/2022	5	-28	-34	-34	N/A
9/30/2022	5	-29	-29	-29	N/A
6/30/2022	5	-31	-24	-24	N/A
3/31/2022	6	-30	-20	-20	N/A
12/31/2021	8	-29	-17	-17	N/A
9/30/2021	9	-28	-18	-18	N/A
6/30/2021	11	-28	-19	-19	N/A
3/31/2021	9	-31	-17	-17	N/A
12/31/2020	7	-34	-15	-15	N/A
9/30/2020	7	-31	-15	-15	N/A
6/30/2020	6	-28	-15	-15	N/A
3/31/2020	5	-30	-22	-22	N/A
12/31/2019	5	-31	-28	-28	N/A
9/30/2019	5	-35	-32	-31	N/A
6/30/2019	5	-39	-35	-35	N/A
3/31/2019	5	-36	-32	-32	N/A
12/31/2018	4	-33	-29	-28	N/A
9/30/2018	4	-30	-25	-25	N/A
6/30/2018	4	-26	-21	-21	N/A
3/31/2018	4	-25	N/A	-20	N/A
12/31/2017	4	-24	N/A	-19	N/A
9/30/2017	3	-23	N/A	-19	N/A
6/30/2017	3	-23	N/A	-20	N/A
3/31/2017	3	-22	N/A	-20	N/A
12/31/2016	3	-22	N/A	-20	N/A
9/30/2016	3	-20	N/A	-18	N/A
6/30/2016	4	-18	N/A	-17	N/A
3/31/2016	4	-16	N/A	-15	N/A
12/31/2015	4	-14	N/A	-12	N/A
9/30/2015	3	-11	N/A	-10	N/A
6/30/2015	2	-9	N/A	-7	N/A
3/31/2015	2	-8	N/A	-6	N/A
12/31/2014	1	-7	N/A	-6	N/A
12/31/2013	1	-3	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SIGHT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SIGHT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SIGHT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SIGHTの収益 ( 33.5% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: SIGHTの収益 ( 33.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SIGHTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

GenSight Biologics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 12%, EPS upgraded

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Recent updates

New major risk - Financial position

GenSight Biologics Announces Submission of LUMEVOQ Dossier to ANSM to Prepare for Restart of Early Access Program in France

First half 2024 earnings released: €0.071 loss per share (vs €0.26 loss in 1H 2023)

New major risk - Financial position

New major risk - Share price stability

GenSight Biologics S.A. Provides Business Update

Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

GenSight Biologics S.A. to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Revenue and earnings growth

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

New major risk - Shareholder dilution

GenSight Biologics S.A. has completed a Follow-on Equity Offering in the amount of €5 million.

Gensight Biologics S.A. Announces CFO Changes

New minor risk - Shareholder dilution

GenSight Biologics Announces Board Changes

GenSight Biologics S.A. Announces CEO Changes

Consensus revenue estimates decrease by 12%, EPS upgraded

Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq

GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ

GenSight Biologics Announces Successful Manufacture of LUMEVOQ GMP Batch

First half 2023 earnings released: €0.26 loss per share (vs €0.23 loss in 1H 2022)

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy

GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

Price target decreased to €10.67

Insufficient new directors

Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?

GenSight Biologics S.A Announces Successful Completion of LUMEVOQ Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality

Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?

Insufficient new directors

First half 2022 earnings released

Insufficient new directors

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Price target decreased to €12.50

GenSight Biologics Grants Six-Month Extension in LUMEVOQ® European Regulatory Review

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 19%

Price target decreased to €12.50

GenSight Biologics S.A. Provides Update on LUMEVOQ® Manufacturing Timeline

Gensight Biologics to Present Reflect Phase III Data with LUMEVOQ® At the NANOS 2022 Meeting

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of Lumevoq® in Europe

GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy

Forecast to breakeven in 2024

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

Price target decreased to €15.00

Price target decreased to €16.00

GenSight Biologics S.A. Announces Positive Data Safety Monitoring Board Review of Pioneer Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ

Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt

First half 2021 earnings released: €0.19 loss per share (vs €0.43 loss in 1H 2020)

GenSight Biologics S.A. Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use in France

Gensight Biologics Reports Topline Results from Reflect Phase III Clinical Trial, Confirming Lumevoq® Efficacy Including Better Efficacy with Bilateral Treatment

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ versus Natural History in Frontiers in Neurology

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

GenSight Biologics S.A. Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye